5. CONCLUSIONS
Upon detailed examination of the formulation, no toxic effect was found in the different trials. Counting of micronucleus was normal, and the overall irritation score showed no significant differences when compared with the negative control. No presence of rapamycin in peripheral blood was found and no genotoxic damage was noted. Furthermore, the different histological, metabolic, biochemical and hematological evaluations demonstrated no rapamycin-related harmful effects after subconjunctival injection. Also, conservation of retina function after intravitreal injection was demonstrated. The liposome-encapsulated rapamycin formulation challenged in this article is safe to use in a dose range from 40 to 440 µg/eye in the different animal models experimented by subconjunctival or intravitreal injection. Furthermore, it shows great potential to be proven in a human clinical trial.